515 related articles for article (PubMed ID: 22005056)
1. New Delhi metallo-β-lactamase (NDM-1): an update.
Shakil S; Azhar EI; Tabrez S; Kamal MA; Jabir NR; Abuzenadah AM; Damanhouri GA; Alam Q
J Chemother; 2011 Oct; 23(5):263-5. PubMed ID: 22005056
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.
Bush K; Fisher JF
Annu Rev Microbiol; 2011; 65():455-78. PubMed ID: 21740228
[TBL] [Abstract][Full Text] [Related]
4. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
6. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
7.
Cervino I; Gonzalez D; Nastro M; Vega J; Reyes AP; Buriano G; Vay C; Famiglietti A; Rodriguez CH
J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763
[TBL] [Abstract][Full Text] [Related]
8. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
Bush K
Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
[TBL] [Abstract][Full Text] [Related]
9. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
Jean SS; Gould IM; Lee WS; Hsueh PR;
Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
[TBL] [Abstract][Full Text] [Related]
10. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
[TBL] [Abstract][Full Text] [Related]
11. Metallo-β-lactamases: a last frontier for β-lactams?
Cornaglia G; Giamarellou H; Rossolini GM
Lancet Infect Dis; 2011 May; 11(5):381-93. PubMed ID: 21530894
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
Wenzler E; Deraedt MF; Harrington AT; Danizger LH
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):352-354. PubMed ID: 28602518
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
Li H; Estabrook M; Jacoby GA; Nichols WW; Testa RT; Bush K
Antimicrob Agents Chemother; 2015 Mar; 59(3):1789-93. PubMed ID: 25534728
[TBL] [Abstract][Full Text] [Related]
15. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
[TBL] [Abstract][Full Text] [Related]
16. A review of the pharmacokinetics and pharmacodynamics of aztreonam.
Ramsey C; MacGowan AP
J Antimicrob Chemother; 2016 Oct; 71(10):2704-12. PubMed ID: 27334663
[TBL] [Abstract][Full Text] [Related]
17. New Delhi Metallo-β-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis.
Lohans CT; Brem J; Schofield CJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971873
[No Abstract] [Full Text] [Related]
18. Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-β-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.
Senchyna F; Murugesan K; Rotunno W; Nadimpalli SS; Deresinski S; Banaei N
Clin Infect Dis; 2024 Jun; 78(6):1425-1428. PubMed ID: 38289725
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).
Shen B; Yu Y; Chen H; Cao X; Lao X; Fang Y; Shi Y; Chen J; Zheng H
PLoS One; 2013; 8(5):e62955. PubMed ID: 23675445
[TBL] [Abstract][Full Text] [Related]
20. [Betalactamase inhibitors].
Timoşca S; Liscă M
Rev Med Chir Soc Med Nat Iasi; 1982; 86(1):35-41. PubMed ID: 25591246
[No Abstract] [Full Text] [Related]
[Next] [New Search]
